Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02842203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from University of Pittsburgh

Record History

  1. Primary and study completion pushed from Sep 2026 to Sep 2027 Eligibility criteria expanded, about 6 words · Study description revised · Publications: details revised at 1 of 1 entry Show 3 more changesShow less
    • Eligibility criteria expanded, about 6 words
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  2. Primary and study completion dates: Sep 2025 to Sep 2026v12
  3. Study Identification, Study Statusv11
  4. Study Identification, Study Status, Sponsor/Collaborators, Oversightv10
  5. 2 versions Re-verified since Oct 7, 2022, no change to tracked fieldsv8-v9
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: Sep 2021 to Sep 2025v7
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 150 to confirmed 137 · Site details revisedv6 Show 2 more changesShow less
    • Enrollment target: estimated 150 to confirmed 137
    • Site details revised
  3. 3 versions Re-verified since Feb 2, 2018, no change to tracked fieldsv3-v5
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
Trial Details
NCT Number NCT02842203
Lead Sponsor University of Pittsburgh
Collaborators: National Cancer Institute (NCI)
Conditions Stage III Colorectal Cancer
Enrollment 137 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov